Ina Qvist1, Rikke Søgaard2, Jes S Lindholt3, Vibeke Lorentzen4, Jesper Hallas5, Lars Frost6. 1. Department of Cardiology, Diagnostic Centre, Regional Hospital Central Jutland, Silkeborg, Denmark; Centre for Research in Clinical Nursing, Regional Hospital Viborg, Viborg, Denmark; Department of Clinical Medicine, Aarhus University, Denmark. Electronic address: inaqvist@rm.dk. 2. Department of Clinical Medicine, Aarhus University, Denmark; Department of Public Health, Aarhus University, Aarhus, Denmark. 3. Department of Vascular Surgery, Regional Hospital Central Jutland, Viborg, Denmark; Centre of Individualised Medicine in Arterial Diseases, Department of Cardiothoracic and Vascular Department T, Odense University Hospital, Odense, Denmark. 4. Centre for Research in Clinical Nursing, Regional Hospital Viborg, Viborg, Denmark; Department of Clinical Medicine, Aarhus University, Denmark. 5. Department of Clinical Chemistry and Pharmacology, Odense University Hospital, Odense, Denmark. 6. Department of Cardiology, Diagnostic Centre, Regional Hospital Central Jutland, Silkeborg, Denmark; Department of Clinical Medicine, Aarhus University, Denmark.
Abstract
OBJECTIVE: Adherence to antiplatelet and statin therapy in participants diagnosed with abdominal aortic aneurysm (AAA) or peripheral arterial disease (PAD) was examined in a vascular screening trial. METHODS: This was a population based cohort study. The study population consisted of 65-74 year old men diagnosed with AAA or PAD in the Viborg Vascular (VIVA) multifaceted screening trial for CVD. Data from the VIVA screening cohort were linked to data from Danish registers from 2007 to 2016. Initiation of antiplatelet and statin treatment was measured within 120 days after screening. Persistence was defined as no treatment gap >100 days between two prescription renewals after screening. A proportion of days covered ≥80% over five years of follow up was used as a categorical cut off for adherence. RESULTS: Among the 18,748 screened participants, 618 with AAA and 2051 with PAD were identified. Among non-users at baseline, 65% and 62% initiated antiplatelet and statin treatment, 57% and 59% persisted with antiplatelet and statin use, and 60% and 57% were adherent, respectively. Among users at baseline, 73% and 69% had filled an antiplatelet or statin prescription, respectively, within 120 days after screening. Further, 79% and 73% persisted with their antiplatelet and statin treatment, and 89% and 83% were adherent, respectively. CONCLUSION: In a vascular screening trial, six of every 10 non-users initiated preventive treatment; among these, the adherence rate was 57-60%. Among users at baseline, the five year adherence to antiplatelet and statin treatment exceeded 80%. The effectiveness of screening initiatives might be improved by measures to improve the fulfilment of preventive medication.
RCT Entities:
OBJECTIVE: Adherence to antiplatelet and statin therapy in participants diagnosed with abdominal aortic aneurysm (AAA) or peripheral arterial disease (PAD) was examined in a vascular screening trial. METHODS: This was a population based cohort study. The study population consisted of 65-74 year old men diagnosed with AAA or PAD in the Viborg Vascular (VIVA) multifaceted screening trial for CVD. Data from the VIVA screening cohort were linked to data from Danish registers from 2007 to 2016. Initiation of antiplatelet and statin treatment was measured within 120 days after screening. Persistence was defined as no treatment gap >100 days between two prescription renewals after screening. A proportion of days covered ≥80% over five years of follow up was used as a categorical cut off for adherence. RESULTS: Among the 18,748 screened participants, 618 with AAA and 2051 with PAD were identified. Among non-users at baseline, 65% and 62% initiated antiplatelet and statin treatment, 57% and 59% persisted with antiplatelet and statin use, and 60% and 57% were adherent, respectively. Among users at baseline, 73% and 69% had filled an antiplatelet or statin prescription, respectively, within 120 days after screening. Further, 79% and 73% persisted with their antiplatelet and statin treatment, and 89% and 83% were adherent, respectively. CONCLUSION: In a vascular screening trial, six of every 10 non-users initiated preventive treatment; among these, the adherence rate was 57-60%. Among users at baseline, the five year adherence to antiplatelet and statin treatment exceeded 80%. The effectiveness of screening initiatives might be improved by measures to improve the fulfilment of preventive medication.
Authors: Martin Wawruch; Jan Murin; Tomas Tesar; Martina Paduchova; Miriam Petrova; Denisa Celovska; Beata Havelkova; Michal Trnka; Emma Aarnio Journal: Front Pharmacol Date: 2021-05-19 Impact factor: 5.810
Authors: Martin Wawruch; Jan Murin; Tomas Tesar; Martina Paduchova; Miriam Petrova; Denisa Celovska; Petra Matalova; Beata Havelkova; Michal Trnka; Emma Aarnio Journal: Biomedicines Date: 2021-11-30